STEK
Stemtech Corporation0.0014
-0.0002-12.5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
204.65KP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Stemtech's Q3 sales fell 17% y/y to $852K yet gross profit climbed 5% to $682K on 80% lower COGS, while operating expenses dropped 25% to $1.0M, narrowing operating loss to $339K from $716K. Net loss improved to $813K, driven by lower interest expense, but exceeded operating loss due to $509K interest. Cash held flat at $255K amid $611K operating burn, offset by $391K financing; total debt rose to $4.1M with $749K factoring liability. Shares outstanding climbed to 159M. Defaults on MCA financing loom large.
10-Q
Q2 FY2025 results
Stemtech's Q2 sales fell 47% y/y to $697.9k yet gross profit held at $552k with margins expanding to 79.1% from 74.9%, while operating expenses plunged 49% to $853k, trimming the operating loss to $301k from $692k. Net loss narrowed to $296k, or $(0.00) per share on 142M diluted shares, versus $784k last year, thanks to lower interest expense and higher other income offsetting the operating gap. Cash edged up to $272k, propped by $552k in financing against $636k operating burn; debt climbed to $4.1M amid $857k factoring liability, with stockholders' deficit at $6.5M. Ongoing litigation over $267k claim persists. Distributors drive sales across North America, Latin America, Asia.
10-Q
Q1 FY2025 results
Stemtech's Q1 FY2025 sales fell 37% y/y to $868K while gross profit held firm at $720K thanks to COGS dropping 57% y/y to $148K, lifting gross margin to 82.9% from 75.0%. Operating loss widened to $1.2M from $1.0M as G&A edged up, yet non-op expenses halved to $254K on lower interest. Net loss ticked to $1.46M ($0.01 per share, anti-dilutive warrants excluded). Cash climbed to $306K; notes payable rose to $2.4M while factoring eased. Debt funds the burn. Ongoing litigation risks linger.
10-K
FY2024 results
Stemtech posted FY2024 net sales of $5.1M, up 2.7% y/y from $4.9M, with gross profit at $3.7M but operating loss narrowing to $2.4M from $4.2M on slashed G&A expenses to $5.2M. Latin America drove 53% of sales at $2.7M, while Americas added $2.2M; no quarterly breakdowns disclosed. Net loss improved to $3.8M from $5.4M, yet interest ate $1.6M and stockholders' deficit swelled to $5.2M amid $9M current liabilities. Cash ticked to $255K via $1.1M financing. No guidance given. Ongoing litigation risks quarterly cash burn.
8-K
CFO resigns, successor named
IPO
Website
Sector
Industry
BIOE
Bio Essence Corp.
0.05+0.00
BSEM
BioStem Technologies, Inc.
3.84-0.11
GELS
Gelteq Limited
0.96+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
ISCO
International Stem Cell Corp.
0.14-0.03
KOAN
Resonate Blends Inc.
0.00+0.00
MTEX
Mannatech, Incorporated
8.33+0.01
NSTM
NovelStem International Corp.
0.02+0.00
RMTG
Regenerative Medical Technology
0.04+0.00
STME
Stimcell Energetics, Inc.
0.37-0.04